Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent's IBI939 is First TIGIT Inhibitor to Start China Trials

publication date: May 26, 2020

Suzhou Innovent Bio has dosed the first patient in a China Phase I trial of its TIGIT candidate, a mAb that binds the anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT). IBI939, which will be tested in patients with advanced malignancies, is the first China TIGIT candidate to start clinical trials. It will be administered as a monotherapy and in combination with Innovent's approved anti-PD-1 drug, Tyvyt®. Innovent says IBI939 disturbs the interaction between CD155 and TIGIT, which weakens the inhibition and depletion of T cells and NK cells. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.